10-Q: Assembly Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

Assembly Biosciences reports a net loss of $8.8 million for Q1 2025, alongside progress in its clinical programs and collaboration with Gilead Sciences.

Summary

• Assembly Biosciences reported a net loss of $8.8 million for the first quarter of 2025, compared to a net loss of $9.1 million for the same period in 2024.
• Collaboration revenue from a related party (Gilead) increased to $9.4 million from $5.8 million year-over-year.
• Research and development expenses increased to $14.9 million from $11.9 million year-over-year, driven by the advancement of clinical programs.
• General and administrative expenses decreased slightly to $4.5 million from $4.6 million year-over-year.
• Cash and cash equivalents totaled $23.4 million as of March 31, 2025, with marketable securities at $67.6 million.
• The company believes it has sufficient funds to meet operating requirements into the middle of 2026.
• Assembly Biosciences sold 161,645 shares of common stock under the 2024 ATM equity offering program, generating net proceeds of $1.9 million.
• The company is advancing multiple clinical-stage investigational therapies, including HPIs for recurrent genital herpes, an HDV entry inhibitor, and a next-generation CAM for chronic HBV infection.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there's progress in clinical programs and a strong collaboration with Gilead. The cash runway extending into mid-2026 provides some stability.

Positives

• Collaboration revenue from Gilead Sciences increased, indicating a strengthening partnership and financial support.
• The company is actively advancing multiple clinical programs, suggesting a robust pipeline and potential for future revenue generation.
• The company believes it has sufficient funds to meet operating requirements into the middle of 2026.
• Positive interim data from clinical studies of ABI-5366 and ABI-1179 support further development of these candidates.
• The nomination of ABI-7423 as a development candidate expands the company's pipeline and potential therapeutic areas.

Negatives

• The company continues to operate at a net loss, indicating ongoing reliance on external funding.
• Research and development expenses are increasing, which may strain financial resources if clinical programs do not progress successfully.
• The company has not derived any revenue from product sales to date and currently has no approved products.

Risks

• The company's success depends on the future success of product candidates in its research and development pipeline.
• The company may not be successful in raising any necessary additional capital on terms that are acceptable.
• The company expects its collaboration with Gilead to be a critical part of the development, manufacture and commercialization of its product candidates.
• Nonclinical and clinical studies required for the company's product candidates are expensive and time-consuming and may fail to demonstrate the level of safety and efficacy necessary for product approval.
• The company relies on CROs to conduct some of its nonclinical and clinical studies due to its lack of suitable facilities and resources.
• Developments by competitors might render the company's product candidates or technologies obsolete or non-competitive.

Future Outlook

Assembly Biosciences expects its existing cash, cash equivalents, and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the middle of 2026.

Industry Context

Assembly Biosciences is operating in a competitive landscape with other companies developing treatments for viral diseases like HBV, HDV, and herpes. The company's collaboration with Gilead is a significant factor, as is the progress of its clinical programs relative to competitors.

Comparison to Industry Standards

• Assembly Biosciences is developing therapies for HBV, HDV, and herpes, diseases targeted by companies like Gilead, Roche, and Johnson & Johnson.
• The company's capsid assembly modulator (CAM) program for HBV aims to achieve functional cures, a goal pursued by other companies like Arbutus Biopharma and Vir Biotechnology.
• Assembly Biosciences' approach to HDV treatment through entry inhibition is similar to bulevirtide, a therapy already approved in Europe.
• The company's helicase-primase inhibitors (HPIs) for herpes compete with existing nucleoside analogs like acyclovir and valacyclovir, but aim to offer improved efficacy and dosing convenience.

Related Party Transactions

• The company recognized $9.4 million and $5.8 million of collaboration revenue under the Gilead Collaboration Agreement during the three months ended March 31, 2025 and 2024, respectively.
• The company incurred $0.1 million and $0.2 million in reimbursable expenses due to Gilead during the three months ended March 31, 2025 and 2024, respectively.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical progress will directly impact shareholder value.
• Employees: The company's ability to secure funding and advance its pipeline will affect job security and opportunities.
• Patients: Successful development of new therapies will provide new treatment options for viral diseases.
• Gilead: The collaboration's success will impact Gilead's pipeline and strategic interests in viral disease treatments.

Next Steps

• The company expects to move into the Phase 1b portion of the Phase 1a/b study of 1179 in the first half of 2025.
• Interim data from the Phase 1b portion of the 5366 study is expected in fall 2025.
• Interim data from the Phase 1b portion of the 1179 study is expected in fall 2025.
• Interim safety, PK and biomarker data from single-ascending and multiple-ascending doses cohorts in healthy participants in the 6250 Phase 1a study is expected in the third quarter of 2025.
• Data from the 400 mg cohort of the 4334 Phase 1b study is anticipated to be released in the first half of 2025.

Key Dates

Keywords

Assembly Biosciences, Gilead, Clinical Trials, Financial Results, Hepatitis B, Herpes, HBV, HDV, R&D, Biotech